Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Doxorubicin in Non-heavily Pretreated Patients With Selected Advanced Solid Tumors

Trial Profile

Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Doxorubicin in Non-heavily Pretreated Patients With Selected Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2018

At a glance

  • Drugs Lurbinectedin (Primary) ; Doxorubicin
  • Indications Adenocarcinoma; Endometrial cancer; Neuroendocrine tumours; Small cell lung cancer; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors PharmaMar
  • Most Recent Events

    • 20 Feb 2018 According to a PharmaMar media release, results from this trial will be presented at the International Association for the Study of Lung Cancer (IASLC) annual meeting
    • 18 Oct 2017 According to results presented at the 18th World Conference on Lung Cancer, the study was amended to use lower dose of doxorubicin due to hematological malignancies.
    • 18 Oct 2017 Results of expansion cohort (n=48) presented at the 18th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top